Loading...

PE anti-mouse IFN-γ Antibody

Pricing & Availability
Clone
XMG1.2 (See other available formats)
Regulatory Status
RUO
Other Names
Interferon-γ, Immune interferon, Type II interferon, T cell interferon, Macrophage-activating factor (MAF)
Isotype
Rat IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
XMG1.2
PMA/Ionomycin-stimulated BALB/c T-cells were stained with CD3 FITC and XMG1.2 PE
  • XMG1.2
    PMA/Ionomycin-stimulated BALB/c T-cells were stained with CD3 FITC and XMG1.2 PE
Compare all formats See PE spectral data
Cat # Size Price Quantity Check Availability Save
505807 25 µg 32€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
505808 100 µg 88€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

IFN-γ is a potent multifunctional cytokine which is secreted primarily by activated NK cells and T cells. Originally characterized based on anti-viral activities, IFN-γ also exerts anti-proliferative, immunoregulatory, and proinflammatory activities. IFN-γ can upregulate MHC class I and II antigen expression by antigen-presenting cells.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
E. coli-expressed, recombinant mouse IFN-γ
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The IFN-γ antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

ICFC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

ELISA1-4,11,14 or ELISPOT5 Detection: The biotinylated XMG1.2 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified R4-6A2 antibody (Cat. No. 505702/505706) as the capture antibody and recombinant mouse IFN-γ (Cat. No. 575309) as the standard.
ELISA or ELISPOT Capture: The purified XMG1.2 antibody is useful as a capture antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with biotinylated R4-6A2 antibody (Cat. No. 505704) as the detection antibody and recombinant mouse IFN-γ (Cat. No. 575309) as the standard. The LEAF™ purified antibody is suggested for ELISPOT capture (Cat. No. 505812).
Flow Cytometry7,8,12,13,16: The fluorochrome-labeled XMG1.2 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IFN-γ-producing cells within mixed cell populations.
Neutralization1-3,9,10: The XMG1.2 antibody can neutralize the bioactivity of natural or recombinant IFN-γ. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of mouse IFN-γ bioactivity in vivo and in vitro (Cat. No. 505812). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 505834) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).
Additional reported applications (for the relevant formats) include: Western blotting, immunohistochemical staining of frozen tissue sections6,22,23, and immunocytochemistry.
Note: For testing mouse IFN-γ in serum, plasma or supernatant, BioLegend's ELISA Max™ Sets (Cat. No. 430801 to 430806) are specially developed and recommended.

Application References
  1. Abrams J, et al. 1992. Immunol. Rev. 127:5. (ELISA, Neut)
  2. Sander B, et al. 1993. J. Immunol. Meth. 166:201. (ELISA, Neut)
  3. Abrams J, et al. 1995. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.20. (ELISA, Neut)
  4. Yang X, et al. 1993. J. Immunoassay 14:129. (ELISA)
  5. Klinman D, et al. 1994. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.19. (ELISPOT)
  6. Sander B, et al. 1991. Immunol. Rev. 119:65. (IHC)
  7. Ferrick D, et al. 1995. Nature 373:255. (FC)
  8. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  9. Peterson KE, et al. 2000. J. Virol. 74:5363. (Neut)
  10. DeKrey GK, et al. 1998. Infect. Immun. 66:827. (Neut)
  11. Dzhagalov I, et al. 2007. J. Immunol. 178:2113. (ELISA)
  12. Lawson BR, et al. 2007. J. Immunol. 178:5366. (FC)
  13. Lee JW, et al. 2006. Nature Immunol. 8:181. (FC) PubMed
  14. Xu G, et al. 2007. J. Immunol. 179:5358. (ELISA) PubMed
  15. Montfort M, et al.2004. J. Immunol. 173:4084. PubMed
  16. Haring JS, et al. 2008. J. Immunol. 180:2855. (FC) PubMed
  17. Jordan JM, et al. 2008. Infect Immun. 76:3717. PubMed
  18. Tonkin DR, et al. 2008. J. Immunol. 181:4516. PubMed
  19. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
  20. Cui Y, et al. 2009. Invest. Ophth. Vis. Sci. 50:5811. (FC) PubMed
  21. Mykkanen OT, et al. 2014. PLoS One. 9:114790. PubMed
  22. Yokogawa M, et al. 2013. Mol. Carcinog. 52:760. (IHC)
  23. Mottram PL, et al. 1998. J Immunol. 161:602. (IHC)
Product Citations
  1. Sandu I, et al. 2020. Nat Commun. 11:4454. PubMed
  2. Wang HH, et al. 2022. J Biomed Sci. 29:36. PubMed
  3. Miki H, et al. 2020. J Immunol. 204:1892. PubMed
  4. Zhang H, et al. 2022. Eur J Immunol. 52:978. PubMed
  5. Jia JJ, et al. 2022. J Leukoc Biol. 112:157. PubMed
  6. Chakraborty P, et al. 2022. Cancer Res. 82:1969. PubMed
  7. Lu R, et al. 2022. Scand J Immunol. 96:e13177. PubMed
  8. Tu J, et al. 2022. Cancer Sci. 113:2496. PubMed
  9. Liu H, et al. 2022. Cell Rep Med. 3:100660. PubMed
  10. Backlund C, et al. 2022. Proc Natl Acad Sci U S A. 119:e2204078119. PubMed
  11. Kang IH, et al. 2022. iScience. 25:104818. PubMed
  12. Wei M, et al. 2022. Front Immunol. 13:1017574. PubMed
  13. Xu H, et al. 2022. Aging Dis. 13:1875. PubMed
  14. Tan TCJ, et al. 2022. Nat Commun. 13:7796. PubMed
  15. Wang Z, et al. 2022. Cell Rep. 41:111890. PubMed
  16. Chan L, et al. 2022. Cells. 12: . PubMed
  17. Liu H, et al. 2023. Cell Death Differ. :. PubMed
  18. Mandour MF, et al. 2023. Front Med (Lausanne). 9:1057252. PubMed
  19. Kuehm LM, et al. 2021. Cancer Immunol Res. 9:227. PubMed
  20. Khojandi N, et al. 2021. Cancer Immunol Res. 9:214. PubMed
  21. Wight AE, et al. 2022. Proc Natl Acad Sci U S A. 119:e2200757119. PubMed
  22. Wu MJ, et al. 2022. Cancer Discov. 12:812. PubMed
  23. Tan L, et al. 2022. Aging Dis. 13:1562. PubMed
  24. Bradley CP et al. 2017. Cell host & microbe. 22(5):697-704 . PubMed
  25. Wu J et al. 2017. Immunity. 47(6):1114-1128 . PubMed
  26. Toubai T, et al. 2017. Blood Adv. 1.095138889. PubMed
  27. Yu X, et al. 2020. Nat Commun. 11:1110. PubMed
  28. Chen R, et al. 2022. J Mol Cell Biol. 14:. PubMed
  29. Cheng C, et al. 2022. Cell Mol Gastroenterol Hepatol. 15:261. PubMed
  30. Pan Y, et al. 2023. Adv Sci (Weinh). 10:e2206792. PubMed
  31. Wang X, et al. 2023. J Immunother Cancer. 11:. PubMed
  32. Lu C, et al. 2023. Antiviral Res. 212:105556. PubMed
  33. Zhuang WR, et al. 2023. Nat Commun. 14:1675. PubMed
  34. Tan X, et al. 2023. Adv Sci (Weinh). 10:e2206768. PubMed
  35. Martins Nascentes Melo L, et al. 2023. J Immunother Cancer. 11:. PubMed
  36. Li D, et al. 2023. Ann Med. 55:2189295. PubMed
  37. Zuo B, et al. 2023. Clin Transl Oncol. . PubMed
  38. Pandit M, et al. 2023. Nat Commun. 14:2593. PubMed
  39. Yu L, et al. 2023. Front Oncol. 13:1174713. PubMed
  40. Deng G, et al. 2023. Cancers (Basel). 15:. PubMed
  41. Wang Y, et al. 2023. iScience. 26:106630. PubMed
  42. Gao Y, et al. 2023. iScience. 26:106729. PubMed
  43. Vereertbrugghen A, et al. 2023. J Neuroinflammation. 20:120. PubMed
  44. Changsheng H, et al. 2023. Sci Adv. 9:eade4186. PubMed
  45. Yang QC, et al. 2023. iScience. 26:106916. PubMed
  46. Wang H, et al. 2013. J Immunol. 191:6010. PubMed
  47. Kim K, et al. 2016. PLoS One. 11: 0148576. PubMed
  48. Liu Y, et al. 2021. Cell Metabolism. 33(6):1221-1233.e11. PubMed
  49. Chen Y, et al. 2020. Virol Sin. . PubMed
  50. Li X, et al. 2022. Nat Commun. 13:2794. PubMed
  51. Zhou J, et al. 2021. Int J Med Sci. 18:3516. PubMed
  52. Kim D, et al. 2021. Nanomicro Lett. 13:31. PubMed
  53. Lin W, et al. 2020. Theranostics. 10:4871. PubMed
  54. Zhou J, et al. 2019. Immunity. 50:403. PubMed
  55. Shi L, et al. 2019. Theranostics. 9:4115. PubMed
  56. Alissafi T, et al. 2018. J Clin Invest. 128:3840. PubMed
  57. Gern BH, et al. 2021. Cell Host Microbe. 29(4):594-606.e6. PubMed
  58. Yang F, et al. 2021. Front Microbiol. 11:512581. PubMed
  59. Kiritsy MC, et al. 2021. Elife. 10:. PubMed
  60. Stegelmeier AA, et al. 2022. Biomedicines. 10:. PubMed
  61. Chen L, et al. 2022. Mol Ther Oncolytics. 24:522. PubMed
  62. Liang S, et al. 2022. Acta Pharm Sin B. 12:2494. PubMed
  63. Coleby R, et al. 2021. Clin Exp Rheumatol. :39. PubMed
  64. Zhang S, et al. 2022. Cell Death Dis. 13:844. PubMed
  65. Gálvez-Cancino F, et al. 2017. Vaccine. 10.1016/j.vaccine.2017.06.041. PubMed
  66. Wang X, et al. 2018. Int Immunopharmacol. 56:249. PubMed
  67. Liu QZ, et al. 2018. Front Immunol. 1.131944444. PubMed
  68. Xia S, et al. 2014. J Leukoc Biol. 95:733. PubMed
  69. Su N, Xiong Y 2016. Sci Rep. 6:22658. PubMed
  70. Dong L, et al. 2021. Cancer Cell. . PubMed
  71. Mayer RL, et al. 2022. Nat Commun. 13:6075. PubMed
  72. Snyder LM, et al. 2021. PLoS Pathog. 17:e1009970. PubMed
  73. Nagatake T, et al. 2022. Mucosal Immunol. 15:289. PubMed
  74. Herman JD, et al. 2021. Nat Commun. 12:6853. PubMed
  75. Galeano Niño JL, et al. 2020. J Cell Sci. . PubMed
  76. Saito S, et al. 2020. Nutrients. 12:. PubMed
  77. Chakrabarti J, et al. 2018. Oncotarget. 9:37439. PubMed
  78. Oyarce C, et al. 2018. Front Immunol. 8:1794. PubMed
  79. Tang Y, et al. 2020. Front Immunol. 11:585918. PubMed
  80. Papafragkos I, et al. 2022. Front Immunol. 13:889075. PubMed
  81. Xiong A, et al. 2022. EBioMedicine. 83:104239. PubMed
  82. Chen D, et al. 2018. Nat Commun. 9:873. PubMed
  83. Koenecke C, et al. 2012. J Immunol. 189:2890. PubMed
  84. Michel M, et al. 2012. Proc Natl Acad Sci U S A. 109:17459. PubMed
  85. Wang Y, et al. 2016. Sci Rep. 6:31881. PubMed
  86. Dai B, et al. 2022. Theranostics. 12:7603. PubMed
  87. Kuttke M, et al. 2022. Front Immunol. 13:695576. PubMed
  88. Xu X, et al. 2021. J Nanobiotechnology. 19:376. PubMed
  89. Subbiah J, et al. 2022. NPJ Vaccines. 7:68. PubMed
  90. Wang C, et al. 2021. Cell Rep. 37:110021. PubMed
  91. Pan W et al. 2017. Immunity. 47(2):284-297 . PubMed
  92. Ning X, et al. 2019. Mol Cell. 74:19. PubMed
  93. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  94. Lv H, et al. 2020. Cell Metabolism. 33(1):110-127.e5. PubMed
  95. Alissafi T, et al. 2020. Cell Metabolism. 32(4):591-604.e7. PubMed
  96. Sharma S, et al. 2015. J Immunol. 194:5529. PubMed
  97. An J, et al. 2022. iScience. 25:103570. PubMed
  98. Han JP, et al. 2022. Sci Adv. 8:eabj6901. PubMed
  99. Yu Y, et al. 2022. Nat Commun. 13:6357. PubMed
  100. Uchil PD et al. 2018. Cell host & microbe. 25(1):87-100 . PubMed
  101. Probst P, et al. 2017. Cancer Res. 77:3644. PubMed
  102. Caronni N, et al. 2018. Cancer Res. 78:1685. PubMed
  103. Wan Y, et al. 2014. Vaccine. 41:241. PubMed
  104. Sandrock I, et al. 2015. PLoS One. 10: 0145010. PubMed
  105. Koren N, et al. 2021. Cell Host Microbe. 29(2):197-209.e5. PubMed
  106. Srey MT, et al. 2020. PLoS Negl Trop Dis. 14:e0008842. PubMed
  107. Chen D, et al. 2022. J Neuroinflammation. 19:112. PubMed
  108. Cha SE, et al. 2021. Oncoimmunology. 10:1899469. PubMed
  109. Canton J, et al. 2021. Nat Immunol. 22:140. PubMed
  110. Hegde S, et al. 2020. Cancer Cell. 37(3):289-307. PubMed
  111. Shami A, et al. 2015. Sci Rep. 5: 13904. PubMed
  112. Gungor B, et al. 2014. Sci Transl Med. 6:235. PubMed
  113. Duan RN, et al. 2021. J Neuroinflammation. 18:145. PubMed
  114. Hanasoge Somasundara AV, et al. 2021. Cell Rep. 37:110099. PubMed
  115. Cheng B, et al. 2022. Cancer Commun (Lond). 42:17. PubMed
  116. Espinosa JR, et al. 2018. Front Immunol. 9:1371. PubMed
  117. Hundt M, et al. 2009. J Immunol. 183:1685. PubMed
  118. Cho K, Hill A 2008. J Immunol Methods. 330:137. PubMed
  119. Condotta S, et al. 2015. J Immunol. 195: 116 - 125. PubMed
  120. Satoh M, et al. 2016. Sci Rep. 6:28473. PubMed
  121. Gong Y, et al. 2020. Cell Metabolism. 33(1):51-64.e9. PubMed
  122. Reese B, et al. 2020. J Immunol. 205:3218. PubMed
  123. Mirando AC, et al. 2020. Oncoimmunology. 9:1760685. PubMed
  124. Garo LP, et al. 2019. Cell Rep. 28:3353. PubMed
  125. Li W, et al. 2019. Nat Commun. 10:3349. PubMed
  126. Yan Y, et al. 2018. JCI Insight. 3. PubMed
  127. Place D, et al. 2017. PLoS One. 10.1371/journal.pone.0190384. PubMed
  128. Palazon A, et al. 2017. Cancer Cell. . 10.1016/j.ccell.2017.10.003. PubMed
  129. Brigas HC, et al. 2021. Cell Reports. 36(9):109574. PubMed
  130. Sartorius R, et al. 2015. EMBO Mol Med. 7: 973 - 988. PubMed
  131. Bosnjak B, et al. 2021. Front Immunol. 12:772240. PubMed
  132. Tian X, et al. 2022. J Cell Mol Med. 26:693. PubMed
  133. Marcus A et al. 2018. Immunity. 49(4):754-763 . PubMed
  134. Ma Y, et al. 2013. J Immunol. 190:5588. PubMed
  135. Dutow P, et al. 2014. J Infect Dis. 209:1269. PubMed
  136. QT N, et al. 2015. Antimicrob Agents Chemother. 59: 6308-6316. PubMed
  137. Latasa C, et al. 2016. PLoS One. 11: 0161216. PubMed
  138. Holokai L, et al. 2020. Cancers (Basel). 12:00. PubMed
  139. Galeano Niño JL, et al. 2020. J Cell Sci. 133:00:00. PubMed
  140. Vaena S, et al. 2021. Cell Reports. 35(5):109076. PubMed
  141. Yang Z, et al. 2021. Onco Targets Ther. 14:4239. PubMed
  142. De Ponte Conti B, et al. 2021. Elife. 10:. PubMed
  143. Tanaka Y, et al. 2020. Sci Rep. 10:17284. PubMed
  144. Ohtsuka J, et al. 2021. iScience. Online ahead of print. PubMed
  145. Lu J, et al. 2021. Cell Death Discov. 7:165. PubMed
  146. Kraus Z, et al. 2008. J Immunol. 181:7800. PubMed
  147. Lin W, et al. 2019. EBioMedicine. 49:133. PubMed
  148. Leclerc M, et al. 2019. Nat Commun. 10:3345. PubMed
  149. Nagatake T, et al. 2018. Int Immunol. 30:471. PubMed
  150. Chatterjee S et al. 2017. Cell metabolism. 27(1):85-100 . PubMed
  151. Yan J, et al. 2020. Cell Rep. 107820:31. PubMed
  152. Shen JZ, et al. 2020. Cell. 184(2):352-369.e23. PubMed
  153. Ren Y, et al. 2015. Sci Rep. 5: 18099. PubMed
  154. Xu Q, et al. 2021. Theranostics. 11:1937. PubMed
  155. Guo S, et al. 2021. Sci Rep. 11:23745. PubMed
  156. Karandikar SH, et al. 2019. JCI Insight. 5. PubMed
  157. Bartolacci C, et al. 2018. Cancer Immunol Res. 1.281944444. PubMed
  158. Montfort M, et al. 2004. J Immunol. 173:4084. PubMed
  159. Koelwyn GJ, et al. 2020. Nat Med. 1452:26. PubMed
  160. Xu P, et al. 2020. Cancer Immunol Res. 8:1193. PubMed
  161. Dong M, et al. 2022. J Immunother Cancer. 10:. PubMed
  162. Ye Q, et al. 2022. NPJ Vaccines. 7:84. PubMed
  163. Stephens WZ, et al. 2021. Cell Rep. 37:109916. PubMed
  164. Kalafati L, et al. 2020. Cell. 183:771. PubMed
  165. Roy S, et al. 2019. Front Immunol. 2.404166667. PubMed
  166. Yuan X, et al. 2017. Elife. 6:e29540. PubMed
  167. Nagatake T, et al. 2018. J Allergy Clin Immunol. 142:470. PubMed
  168. Zhang J, et al. 2018. Nature. 553:91. PubMed
  169. Wang Y, et al. 2020. Virol Sin. 36:122. PubMed
  170. Hirata SI, et al. 2020. Allergy. 75:1939. PubMed
  171. Castiglioni P, et al. 2017. PLoS Negl Trop Dis. 10.1371/journal.pntd.0005240. PubMed
  172. Cartwright ANR, et al. 2021. Cancer Immunol Res. 9:470. PubMed
  173. Li H, et al. 2021. Front Immunol. 12:739605. PubMed
  174. Kiritsy MC, et al. 2021. Elife. 10:. PubMed
  175. Raju S, et al. 2020. Cell Reports. 29(9):2556-2564.e3.. PubMed
  176. Mandour MF, et al. 2020. Infect Agent Cancer. 15:30. PubMed
  177. Miura N, et al. 2017. Mol Ther. 10.1016/j.ymthe.2017.01.020. PubMed
  178. Miao W, et al. 2020. J Immunol. 1486:204. PubMed
  179. Ma Q, et al. 2022. Vaccines (Basel). 10:. PubMed
  180. Kim MY, et al. 2022. Nat Commun. 13:3296. PubMed
  181. Johnson RM, et al. 2021. Front Immunol. 11:614697. PubMed
  182. Tian D, et al. 2019. Nat Commun. 10:4246. PubMed
  183. Mah-Som AY, et al. 2021. Cell Reports. 35(9):109209. PubMed
  184. Lee J, et al. 2007. Nat Immunol. 8:181. PubMed
  185. Fang W, et al. 2021. J Exp Clin Cancer Res. 40:4. PubMed
  186. Chen L, et al. 2021. Theranostics. 11:6668. PubMed
  187. Rousso-Noori L, et al. 2021. Nat Commun. 12:3615. PubMed
  188. Wang Y, et al. 2021. Front Immunol. 11:601601. PubMed
  189. Prakash MD, et al. 2021. PLoS One. 16:e0247492. PubMed
  190. Zhang X, et al. 2020. J Cancer. 11:648. PubMed
  191. Ding L et al. 2018. Cell reports. 25(11):2972-2980 . PubMed
  192. Tomaru U et al. 2019. Cell reports. 26(3):639-651 . PubMed
  193. Hoechst B, et al. 2016. J Immunol. 195:1517-1523. PubMed
  194. Molgora M, et al. 2020. Cell. 182:886. PubMed
  195. Nakao R, et al. 2022. NPJ Vaccines. 7:153. PubMed
  196. McAusland TM, et al. 2021. Mol Ther Oncolytics. 20:306. PubMed
  197. Li H, et al. 2022. iScience. 25:104481. PubMed
  198. Schmit T, et al. 2022. Cell Rep. 38:110456. PubMed
  199. Zhang X, et al. 2021. Front Pharmacol. 12:706748. PubMed
  200. Liu X, et al. 2021. Adv Sci (Weinh). 8:e2100233. PubMed
  201. Chakraborty P, et al. 2020. Cell Reports. 28(7):1879-1893.e7.. PubMed
  202. Zhao K, et al. 2021. Biomed Res Int. 7619849:2020. PubMed
  203. Charlton J, et al. 2015. PLoS One. 10:119200. PubMed
  204. Dourcy M, et al. 2020. Mucosal Immunol. 13:799. PubMed
  205. Kerdidani D, et al. 2022. J Exp Med. 219:. PubMed
  206. Zheng Y, et al. 2022. Transl Res. :. PubMed
  207. Timilshina M, et al. 2020. Cell Reports. 27(10):2948-2961.e7.. PubMed
  208. Kim YS, et al. 2018. Front Immunol. 9:1093. PubMed
  209. Wang N, et al. 2020. Front Immunol. 1.765972222. PubMed
  210. Gaylo A, et al. 2013. Transpl Immunol. 20:163. PubMed
  211. Chen PM, et al. 2022. Sci Adv. 8:eabo4271. PubMed
  212. Song X, et al. 2022. Transl Oncol. 15:101306. PubMed
  213. Yang F, et al. 2021. Nat Commun. 12:3424. PubMed
  214. Li X, et al. 2021. Front Cell Dev Biol. 9:647713. PubMed
  215. Brenner E, et al. 2020. Nat Commun. 11:1335. PubMed
  216. Qi S, et al. 2020. Theranostics. 10:1814. PubMed
  217. Chen S, et al. 2018. Nat Commun. 9:5298. PubMed
  218. Bing Wu et al. 2018. Immunity. 49(5):886-898 . PubMed
  219. Nabekura T, et al. 2020. Immunity. 96:52. PubMed
  220. Chow AK, et al. 2021. Cellular and Molecular Gastroenterology and Hepatology. :. PubMed
  221. Tripathi D, et al. 2016. Nat Commun. 7:13896. PubMed
RRID
AB_315401 (BioLegend Cat. No. 505807)
AB_315402 (BioLegend Cat. No. 505808)

Antigen Details

Structure
Cytokine; dimer; 40-80 kD (Mammalian)
Bioactivity
Antiviral/antiparasitic activities; inhibits proliferation; enhances MHC class I and II expression on APCs
Cell Sources
CD8+ and CD4+ T cells, NK cells
Cell Targets
T cells, B cells, macrophages, NK cells, endothelial cells, fibroblasts
Receptors
IFN-γRα (CDw119) dimerized with IFN-γRβ (AF-1)
Cell Type
Tregs
Biology Area
Cell Biology, Immunology, Neuroinflammation, Neuroscience
Molecular Family
Cytokines/Chemokines
Antigen References

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego.
2. De Maeyer E, et al. 1992. Curr. Opin. Immunol. 4:321.
3. Farrar M, et al. 1993. Annu. Rev. Immunol. 11:571.
4. Gray P, et al. 1987. Lymphokines 13:151.

Regulation
Upregulated by IL-2, FGF-basic, EGF; downregulated by 1-α-25-Dihydroxy vitamin D3, dexamethasone
Gene ID
15978 View all products for this Gene ID
UniProt
View information about IFN-gamma on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.
Go To Top Version: 2    Revision Date: 12-11-2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account